WCM
ALLO icon

Wildcat Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Wildcat Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.08M Hold
2,920,787
– – 2.66% 2
2026
Q1 		$7.13M Hold
2,920,787
– – 6.71% 2
2025
Q4 		$4M Hold
2,920,787
– – 2.93% 2
2025
Q3 		$3.62M Hold
2,920,787
– – 2.5% 3
2025
Q2 		$3.12M Hold
2,920,787
– – 1.85% 5
2025
Q1 		$4.26M Hold
2,920,787
– – 2.28% 5
2024
Q4 		$6.22M Hold
2,920,787
– – 2.46% 3
2024
Q3 		$8.18M Hold
2,920,787
– – 4% 3
2024
Q2 		$6.81M Buy
2,920,787
+1,000,000
+52% +$2.95M 1.67% 13
2024
Q1 		$7.88M Hold
1,920,787
– – 2.86% 9
2023
Q4 		$6.17M Hold
1,920,787
– – 2.13% 12
2023
Q3 		$6.09M Hold
1,920,787
– – 2.45% 12
2023
Q2 		$9.55M Hold
1,920,787
– – 3.63% 11
2023
Q1 		$9.49M Sell
1,920,787
-207,583
-10% -$1.33M 3.53% 11
2022
Q4 		$13.4M Hold
2,128,370
– – 5.11% 7
2022
Q3 		$23M Hold
2,128,370
– – 8.83% 3
2022
Q2 		$24.3M Hold
2,128,370
– – 8.04% 4
2022
Q1 		$19.4M Buy
2,128,370
+412,000
+24% +$4.29M 4.96% 10
2021
Q4 		$25.6M Hold
1,716,370
– – 4.17% 9
2021
Q3 		$44.1M Hold
1,716,370
– – 5.71% 5
2021
Q2 		$44.8M Buy
1,716,370
+200,846
+13% +$5.73M 5.08% 4
2021
Q1 		$53.5M Hold
1,515,524
– – 6.53% 3
2020
Q4 		$38.3M Hold
1,515,524
– – 4.81% 4
2020
Q3 		$57.1M Hold
1,515,524
– – 18.27% 2
2020
Q2 		$64.9M Buy
1,515,524
+165,882
+12% +$6M 22.42% 1
2020
Q1 		$26.2M Buy
1,349,642
+147,816
+12% +$3.52M 11.95% 3
2019
Q4 		$31.2M Buy
1,201,826
+295,632
+33% +$8.14M 9.01% 4
2019
Q3 		$24.7M Buy
906,194
+374,028
+70% +$10.7M 10.49% 3
2019
Q2 		$14.3M Buy
+532,166
New +$14.8M 6.18% 5

Other funds holding ALLO

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
HDA
Harold Davidson & Associates Los Angeles, California $231M AUM 35.6% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CWMS
CFG Wealth Management Services Indianapolis, Indiana $107M AUM
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
NL
Navalign LLC Encino, California $429M AUM 18.12% 1-Year Est. Return

Wildcat Capital Management's ALLO Position: Q2 2026 in Review

Wildcat Capital Management held its Allogene Therapeutics (ALLO) position steady in Q2 2026 at 2,920,787 shares worth $6.08M. The position accounts for 2.66% of the portfolio, ranked #2.

Wildcat Capital Management first reported a position in ALLO in Q2 2019 and has held it in 29 quarters since. The position peaked at $64.9M in Q2 2020. 37 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Wildcat Capital Management held 2,920,787 shares of Allogene Therapeutics worth $6.08M as of Q2 2026.
  • Wildcat Capital Management left its Allogene Therapeutics share count unchanged in Q2 2026.
  • Allogene Therapeutics made up 2.66% of Wildcat Capital Management's portfolio in Q2 2026, its #2 holding.
  • Wildcat Capital Management first reported a position in Allogene Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • Wildcat Capital Management's Allogene Therapeutics position peaked at $64.9M in Q2 2020.
  • 37 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Wildcat Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.